Elucidating Immunometabolic Responses to HIV Infection that Increase TB or HBV Risk (R21 Clinical Trial Not Allowed)
National Institutes of Health (NIH)
Total budget for direct costs may not exceed $275,000.
Project duration is limited to 2 years.
To support research elucidating how HIV-induced immunometabolic alterations impact immune responses and increase risks for TB and HBV.
Public and private nonprofit institutions, individuals, and organizations involved in biomedical research.
Eligible organization types include higher education institutions, nonprofits, for-profit organizations, small businesses, local and state governments, and federal agencies.
Specific qualifications include being a public or private institution, and certain nonprofits may require 501(c)(3) status.
Eligible applicants include both domestic (U.S.) and non-domestic (foreign) entities.
Non-domestic components of U.S. organizations are also eligible.
Research must focus on HIV immunometabolism and its effects on TB or HBV.
Applications proposing clinical trials are not allowed.
The combined budget for direct costs may not exceed $275,000 over the project period.
No more than $200,000 in direct costs may be requested in any single year.
Applications are due by 5:00 PM local time of the applicant organization.
Key dates include an opening date of April 07, 2025, and a closing date of January 07, 2028.
Applicants may submit more than one application, provided each is scientifically distinct.
The NIH will not accept duplicate or overlapping applications under review at the same time.
Applications must follow the instructions in the Research (R) Instructions in the How to Apply - Application Guide.
Specific forms include SF424(R&R) Cover, Project/Performance Site Locations, and Research Plan.
Applications will be evaluated based on significance, innovation, approach, investigator expertise, and environment.
Applications will undergo a peer review process by appropriate Scientific Review Groups.
Scientific and technical merit, availability of funds, and relevance to program priorities will be considered.
Applications must not propose clinical trials and should focus on exploratory/developmental research.
The requirement for interdisciplinary teams may pose challenges for some applicants.
Leveraging existing clinical samples and applying AI approaches are encouraged.
The focus on novel research areas may provide a competitive edge for innovative proposals.
Strong interdisciplinary collaboration and innovative research approaches are critical.
Avoid submitting overlapping applications and ensure compliance with all application instructions.
Engage with collaborators early and ensure all registrations are completed prior to submission.
Highlight unique aspects of the proposed research and its potential impact on public health.